News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
The role of growth factors in the activity of pharmacological differentiation agents.
|Title||The role of growth factors in the activity of pharmacological differentiation agents.|
|Publication Type||Journal Article|
|Year of Publication||2002|
|Authors||Matsui WH, Gladstone DE, Vala MS, Barber JP, Brodsky RA, Smith DB, Jones RJ|
|Journal||Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research|
|Date Published||2002 Jun|
Bryostatin-1 inhibits acute myeloid leukemia (AML) in vitroat doses that stimulate the growth of normal hematopoietic progenitors.Although bryostatin-1 has a number of distinct biological activities, those specifically responsible for its antileukemic activity are unclear. We found that bryostatin-1 (10(-8) M) inhibited cell cycling at G(1), induced phenotypic evidence of differentiation, and limited the clonogenic growth of both AML cell lines and patient specimens. This activity was markedly enhanced by granulocyte/macrophage-colony stimulating factor, whereas growth factor-neutralizing antibodies completely inhibited both the differentiating and antileukemic activities of bryostatin-1. Cell cycle inhibition and growth factors were also required for the differentiating activities of two unrelated agents, hydroxyurea and phenylbutyrate. These data suggest that many pharmacological differentiating agents require both cell cycle arrest and lineage-specific growth factors for full activity and may explain why these agents have demonstrated only limited clinical efficacy.
|Alternate Journal||Cell Growth Differ.|